Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model

Current Cancer Drug Targets

Volumn 13, Issue 1, 2013, Pages 11-29

  Karra, Nour ^a   Nassar, Taher ^a   Laenger, Florian ^b   Benita, Simon ^a   Borlak, Juergen ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

C raf transgenic mice; Computed tomography imaging; EpCAM drug loaded immunonanoparticles; Proof of concept study; Safety and efficacy; Treatment of lung cancer

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; IMMUNONANOPARTICLE; NANOPARTICLE; PACLITAXEL; RAF PROTEIN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ATOMIC FORCE MICROSCOPY; BLEEDING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG LAVAGE; LUNG VOLUME; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MORTALITY; MOUSE; NANOENCAPSULATION; NEUTROPHIL COUNT; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84875821889     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800913804486647     Document Type: Article

References (62)

1. American Cancer Society. Cancer Facts & Figures 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveila nce/documents/document/acspc-029771.pdf (Accessed September 18, 2011).
2. Gagnadoux, F.; Hureaux, J.; Vecellio, L.; Urban, T.; Le Pape, A.; Valo, I.; Montharu, J.; Leblond, V.; Boisdron-Celle, M.; Lerondel, S.; Majoral, C.; Diot, P.; Racineux, J. L.; Lemarie, E. Aerosolized chemotherapy. J. Aerosol. Med. Pulm. Drug Deliv. 2008, 21, 61-70.
3. Azarmi, S.; Roa, W. H.; Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60, 863-875.
4. Gagnadoux, F.; Pape, A. L. Lemarie, E.; Lerondel, S.; Valo, I.; Leblond, V.; Racineux, J. L.; Urban, T. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur. Respir. J. 2005, 26, 657-661.
5. Hershey, A. E.; Kurzman, I. D.; Forrest, L. J.; Bohling, C. A.; Stonerook, M.; Placke, M. E.; Imondi, A. R.; Vail, D. M. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. 1999, 5, 2653-2659.
6. Garbuzenko, O. B.; Saad, M.; Pozharov, V. P.; Reuhl, K. R.; Mainelis, G.; Minko, T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 10737-10742.
7. Rytting, E.; Bur, M.; Cartier, R.; Bouyssou, T.; Wang, X.; Kruger, M.; Lehr, C. M.; Kissel, T. In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J. Control Release 2010, 141, 101-107.
8. Rytting, E.; Nguyen, J.; Wang, X.; Kissel, T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2008, 5, 629-639.
9. Jensen, D. K.; Jensen, L. B.; Koocheki, S.; Bengtson, L.; Cun, D.; Nielsen, H. M.; Foged, C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control Release 2012, 157, 141-148.
10. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66, 6732-6740.
11. Tseng, C. L.; Wu, S. Y.; Wang, W. H.; Peng, C. L.; Lin, F. H.; Lin, C. C.; Young, T. H.; Shieh, M. J. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29, 3014-3022.
12. Tseng, C. L.; Su, W. Y.; Yen, K. C.; Yang, K. C.; Lin, F. H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30, 3476-3485.
13. Went, P.; Vasei, M.; Bubendorf, L.; Terracciano, L.; Tornillo, L.; Riede, U.; Kononen, J.; Simon, R.; Sauter, G.; Baeuerle, P. A. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br. J. Cancer 2006, 94, 128-135.
14. Gastl, G.; Spizzo, G.; Obrist, P.; Dunser, M.; Mikuz, G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356, 1981-1982.
15. Spizzo, G.; Went, P.; Dirnhofer, S.; Obrist, P.; Simon, R.; Spichtin, H.; Maurer, R.; Metzger, U.; von Castelberg, B.; Bart, R.; Stopatschinskaya, S.; Kochli, O. R.; Haas, P.; Mross, F.; Zuber, M.; Dietrich, H.; Bischoff, S.; Mirlacher, M.; Sauter, G.; Gastl, G. High Ep-CAM expression is associated with poor prognosis in nodepositive breast cancer. Breast Cancer Res. Treat. 2004, 86, 207-213.
16. Varga, M.; Obrist, P.; Schneeberger, S.; Muhlmann, G.; Felgel-Farnholz, C.; Fong, D.; Zitt, M.; Brunhuber, T.; Schafer, G.; Gastl, G.; Spizzo, G. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin. Cancer Res. 2004, 10, 3131-3136.
17. van der Gun, B. T.; Melchers, L. J.; Ruiters, M. H.; de Leij, L. F.; McLaughlin, P. M.; Rots, M. G. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31, 1913-1921.
18. Munz, M.; Baeuerle, P. A.; Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009, 69, 5627-5629.
19. Yamashita, T.; Budhu, A.; Forgues, M.; Wang, X. W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007, 67, 10831-10839.
20. Trzpis, M.; McLaughlin, P. M.; de Leij, L. M.; Harmsen, M. C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395.
21. Winkler, J.; Martin-Killias, P.; Pluckthun, A.; Zangemeister-Wittke, U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 2009, 8, 2674-2683.
22. Das, M.; Sahoo, S. K. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater. 2011, 7, 355-369.
23. Hussain, S.; Pluckthun, A.; Allen, T. M.; Zangemeister-Wittke, U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bclxL. Mol. Cancer Ther. 2006, 5, 3170-3180.
24. Kerkhoff, E.; Fedorov, L. M.; Siefken, R.; Walter, A. O.; Papadopoulos, T.; Rapp, U. R. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ. 2000, 11, 185-190.
25. Rodt, T.; von Falck, C.; Halter, R.; Ringe, K.; Shin, H. O.; Galanski, M.; Borlak, J. In vivo microCT quantification of lung tumor growth in SPC-raf transgenic mice. Front. Biosci. 2009, 14, 1939-1944.
26. Maaser, K.; Borlak, J. A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. Br. J. Cancer 2008, 99, 1635-1643.
27. Debotton, N.; Parnes, M.; Kadouche, J.; Benita, S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J Control Release 2008, 127, 219-230.
28. Goldstein, D.; Nassar, T.; Lambert, G.; Kadouche, J.; Benita, S. The design and evaluation of a novel targeted drug delivery system using cationic emulsion-antibody conjugates. J. Control Release 2005, 108, 418-432.
29. Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55, R1-R4.
30. Bonner, T. I.; Oppermann, H.; Seeburg, P.; Kerby, S. B.; Gunnell, M. A.; Young, A. C.; Rapp, U. R. The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res. 1986, 14, 1009-1015.
31. Rutters, H.; Zurbig, P.; Halter, R.; Borlak, J. Towards a lung adenocarcinoma proteome map: studies with SP-C/c-raf transgenic mice. Proteomics 2006, 6, 3127-3137.
32. Bivas-Benita, M.; Zwier, R.; Junginger, H. E.; Borchard, G. Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 2005, 61, 214-218.
33. Lehner, F.; Kulik, U.; Klempnauer, J.; Borlak, J. The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases. FASEB J. 2007, 21, 1445-1462.
34. Debotton, N.; Zer, H.; Parnes, M.; Harush-Frenkel, O.; Kadouche, J.; Benita, S. A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance. Eur. J. Pharm. Biopharm. 2010, 74, 148-156.
35. Rodt, T.; von Falck, C.; Dettmer, S.; Hueper, K.; Halter, R.; Hoy, L.; Luepke, M.; Borlak, J.; Wacker, F. Lung tumour growth kinetics in SPC-c-Raf-1-BB transgenic mice assessed by longitudinal in-vivo micro-CT quantification. J. Exp. Clin. Cancer Res. 2012, 31, 15.
36. Lehnert, B. E. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ. Health Perspect. 1992, 97, 17-46.
37. Rogueda, P. G.; Traini, D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin. Drug Deliv. 2007, 4, 595-606.
38. Rogueda, P. G.; Traini, D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin. Drug Deliv. 2007, 4, 607-620.
39. Roa, W. H.; Azarmi, S.; Al-Hallak, M. H.; Finlay, W. H.; Magliocco, A. M.; Lobenberg, R. Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J. Control Release. 2010, 150, 49-55.
40. Jiang, H. L.; Xu, C. X.; Kim, Y. K.; Arote, R.; Jere, D.; Lim, H. T.; Cho, M. H.; Cho, C. S. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 2009, 30, 5844-5852.
41. Jiang, H. L.; Hong, S. H.; Kim, Y. K.; Islam, M. A.; Kim, H. J.; Choi, Y. J.; Nah, J. W.; Lee, K. H.; Han, K. W.; Chae, C.; Cho, C. S.; Cho, M. H. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int. J. Pharm. 2011, 420, 256-265.
42. Gunther, M.; Lipka, J.; Malek, A.; Gutsch, D.; Kreyling, W.; Aigner, A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 2010, 77, 438-449.
43. Nielsen, E. J.; Nielsen, J. M.; Becker, D.; Karlas, A.; Prakash, H.; Glud, S. Z.; Merrison, J.; Besenbacher, F.; Meyer, T. F.; Kjems, J.; Howard, K. A. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm. Res. 2010, 27, 2520-2527.
44. Dailey, L. A.; Jekel, N.; Fink, L.; Gessler, T.; Schmehl, T.; Wittmar, M.; Kissel, T.; Seeger, W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 2006, 215, 100-108.
45. Harush-Frenkel, O.; Bivas-Benita, M.; Nassar, T.; Springer, C.; Sherman, Y.; Avital, A.; Altschuler, Y.; Borlak, J.; Benita, S. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol. Appl. Pharmacol. 2010, 246, 83-90.
46. Card, J. W.; Zeldin, D. C.; Bonner, J. C.; Nestmann, E. R. Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L400-411.
47. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 2004, 10, 7382-7391.
48. Liebmann, J.; Cook, J. A.; Lipschultz, C.; Teague, D.; Fisher, J.; Mitchell, J. B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 1994, 33, 331-339.
49. Sparreboom, A.; van Tellingen, O.; Nooijen, W. J.; Beijnen, J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996, 56, 2112-2115.
50. Safety Data Sheet, Cremophor RH 40 Surfactant, BASF, The Chemical Company. http://worldaccount.basf.com (Accessed August 6, 2012).
51. Otterson, G. A.; Villalona-Calero, M. A.; Hicks, W.; Pan, X.; Ellerton, J. A.; Gettinger, S. N.; Murren, J. R. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 2466-2473.
52. Uhrich, K. E.; Cannizzaro, S. M.; Langer, R. S.; Shakesheff, K. M. Polymeric systems for controlled drug release. Chem. Rev. 1999, 99, 3181-3198.
53. Pistner, H.; Gutwald, R.; Ordung, R.; Reuther, J.; Muhling, J. Poly(L-lactide): a long-term degradation study in vivo. I. Biological results. Biomaterials 1993, 14, 671-677.
54. Pistner, H.; Bendix, D. R.; Muhling, J.; Reuther, J. F. Poly(Llactide): a long-term degradation study in vivo. Part III. Analytical characterization. Biomaterials 1993, 14, 291-298.
55. Ignatius, A. A.; Claes, L. E. In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-coglycolide). Biomaterials 1996, 17, 831-839.
56. Latimer, P.; Menchaca, M.; Snyder, R. M.; Yu, W.; Gilbert, B. E.; Sanders, B. G.; Kline, K. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. (Maywood). 2009, 234, 1244-1252.
57. Hansel, T. T.; Kropshofer, H.; Singer, T.; Mitchell, J. A.; George, A. J. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 2010, 9, 325-338.
58. Oberdorster, G.; Maynard, A.; Donaldson, K.; Castranova, V.; Fitzpatrick, J.; Ausman, K.; Carter, J.; Karn, B.; Kreyling, W.; Lai, D.; Olin, S.; Monteiro-Riviere, N.; Warheit, D.; Yang, H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2005, 2, 8.
59. Drent, M.; Cobben, N. A.; Henderson, R. F.; Wouters, E. F.; van Dieijen-Visser, M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur. Respir. J. 1996, 9, 1736-1742.
60. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7, 771-782.
61. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
62. Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell. Biol. 2010, 188, 759-768.